X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery. Coupling X-Chem’s high-quality DEL data with the innovative AI capabilities of Glamorous AI positions X-Chem as a leading service provider in machine learning-driven drug discovery.
“What AlphaFold did for protein folding, X-Chem and Glamorous AI will do for drug discovery,” said Matt Clark, Ph.D., CEO of X-Chem. “Glamorous AI brings cutting-edge solutions to the entire small molecule drug discovery process. By combining the data-generating power of our leading DEL platform with Glamorous’ AI capability, we will accelerate our partners’ drug discovery programs and get medicines to patients faster.”
The move helps accelerate drug discovery and offers several advantages for our customers, including:
- Revolutionizing the discovery of new medicines — expanded capabilities that save time, reduce risk, and yield a higher probability of success from screening to clinical candidate
- The ability to unlock the full potential of rich datasets generated by X-Chem’s technology — rapid identification of high-quality starting points for drug discovery
- The leading AI solution for the entire drug discovery process — merging high-quality, large DEL datasets with sparser medicinal chemistry data to accelerate outcomes
“X-Chem generates billions of high-quality data points with its DEL platform, and we provide the capability to build the best AI to unlock the power of those data. It is when such large datasets come together with powerful technology like AI that transformation happens. This aligns very well with our vision to democratize access to AI and to provide a fully-integrated service for the biopharma industry,” said Glamorous AI CEO Noor Shaker.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
This acquisition, along with the recently announced acquisition of ComInnex, further solidifies X-Chem’s position as the leading provider of innovative solutions in early-stage drug discovery.
Source: Biospace